Immunocore is a commercial-stage company making T cell receptor bispecific drugs; KIMMTRAK is approved for HLA-A*02:01-positive metastatic uveal melanoma, a rare eye cancer, in 39 countries.
Immunocore's case rests on KIMMTRAK, its approved T cell receptor bispecific for uveal melanoma, and on expanding it. Second-quarter KIMMTRAK sales rose 18% to $115.9 million, and five-year data showed 16% of patients alive versus 8% on control. TEBE-AM, a 540-patient Phase 3 in previously treated cutaneous melanoma, could report overall survival as early as the end of 2026. Brenetafusp is in a first-line Phase 3. Cash was $880.2 million against $402.5 million of convertible notes.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: TEBE-AM shows a survival benefit in cutaneous melanoma
Does tebentafusp extend overall survival versus control in previously treated cutaneous melanoma?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Immunocore's TEBE-AM Phase 3 in cutaneous melanoma could read out by year-end
KIMMTRAK sales keep growing while two Phase 3 melanoma readouts approach
KIMMTRAK's commercial momentum funds a Phase 3 OS bet in cutaneous melanoma that will define whether tebentafusp's utility extends beyond its orphan niche
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Lung cancer, Breast and gynecologic cancers, Gastrointestinal cancers, Other cancers, Infectious diseases, Obesity, diabetes and heart disease, Skin diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
40 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.